FUJIFILM ANNOUNCES LAUNCH OF FUJIFILM TOYAMA CHEMICAL

A company for research, development, manufacture and sale of diagnostic and therapeutic drugs

 

October 1, 2018

 

FUJIFILM Corporation (President: Kenji Sukeno) announces the launch of FUJIFILM Toyama Chemical Co., Ltd (President: Junji Okada) on October 1, 2018. The company will engage in the research, development, manufacture and sale of diagnostic and therapeutic drugs.

 

FUJIFILM Toyama Chemical was formed through the merger of TOYAMA CHEMICAL CO., LTD. (Toyama Chemical), a company engaged in the research, development, manufacture and sale of small molecule pharmaceuticals and FUJIFILM RI Pharma Co., Ltd., a company engaged in the research, development, manufacture and sale of radiopharmaceuticals in order to accelerate the development of diagnostic and therapeutic drugs.

 

Together with FUJIFILM Corporation, engaging in activities including new drug research, FUJIFILM Toyama Chemical will seek to develop new diagnostic and therapeutic radiopharmaceuticals and other new pharmaceuticals with unique mechanisms of action to address areas of significant unmet medical needs in the fields of oncology, central nervous system disorders and infectious diseases. In addition, FUJIFILM Toyama Chemical will also strive to develop new drugs that harness "drug delivery systems" designed to precisely deliver the required dose of pharmaceuticals to designated areas of the body at the necessary time. The company will leverage the in vitro diagnostic devices and reagents owned by FUJIFILM Corporation in addition to diagnostics drugs in order to expand its product portfolio to provide total solutions for patients at all stages from diagnosis through to treatment.

 

Pharmaceuticals for which Toyama Chemical had acquired manufacturing and marketing approval and held sales rights are currently being sold by Taisho Toyama Pharmaceutical Co., Ltd., but from April 1, 2019 onwards, these products will be sold by FUJIFILM Toyama Chemical. However, the antibiotic combination product consisting of semisynthetic antibiotic and β-lactamase inhibitor Zosyn, jointly developed together with Taiho Pharmaceutical Co., Ltd., will be sold by Taiho Pharmaceutical Co., Ltd. which has the license of manufacturing and distribution from April 1 2019 onwards.

 

Through its engagement in the pharmaceuticals business, principally through the business activities of FUJIFILM Toyama Chemical, Fujifilm is committed to expanding its business through the creation of innovative pharmaceuticals, while also contributing to resolve various issues facing society.

 

 

 

 

Overview of FUJIFILM Toyama Chemical Co., Ltd.

Company Name

FUJIFILM Toyama Chemical Co.,Ltd.

Address

14-1, Kyobashi 2-Chome, Chuo-ku, Tokyo Japan

Capital

490 million yen (100% owned by FUJIFILM Corporation)

Main Business Activities

Research, development, manufacture, sale, export, and import of pharmaceuticals (diagnostic and therapeutic agents) and related devices

Directors

Director and Chairperson                                 Kenji Sukeno

Representative Director and President,
Corporate Vice President                                     Junji Okada

Director and Senior Executive Vice President          Yoshimitsu Ando

Director and Senior Executive Vice President            Shunichiro Ishikawa

Director and Executive Vice President            Kozo Kobayashi

Outside Director                                              Takatoshi Ishikawa

Outside Director                                       Toshikazu Ban

Auditor                                             Akira Fujisawa

Outside Auditor                                                                  Tetsuo Imada

Corporate Vice President                               Hiroyuki Kasahara

Corporate Vice President                               Ryosuke Yamada

Corporate Vice President                               Takahiro Sanzen

Corporate Vice President                               Takao Yamamoto

Corporate Vice President                               Toshiya Morita

 

 

For inquiries on information in this media release, contact:

Media contact:  Corporate Communications Division                    TEL+81 3-6271-2000

Other:       Pharmaceutical Products Division                         TEL+81 3-6271-2171